Know What's Happening in BioTech

Smartphone Measures Vasomotor Function via Fingertip Elasticity

Researchers published a study demonstrating that a standard smartphone can assess vasomotor function by measuring fingertip arteriolar elasticity using green‑light photoplethysmography combined with a volume‑oscillometric method. The technique captures blood‑volume oscillations to infer arterial pressure changes, offering a non‑invasive proxy...

Cryo-EM Maps Autoantibody Hotspots on NMDA Receptors in Autoimmune Encephalitis

A study in Science Advances used cryo‑electron microscopy to map the exact binding sites of anti‑NMDAR autoantibodies on the GluN1 amino‑terminal domain of NMDA receptors. The researchers showed that mouse‑derived antibodies bind the same two hotspots as those isolated from...

Scribe Therapeutics Plans to Test Cholesterol-Lowering Therapy This Summer

The request does not contain the full text of the article titled “Scribe Therapeutics plans to test cholesterol‑lowering therapy this summer,” only a brief placeholder and a sign‑up prompt. Without the substantive content, no executive summary can be generated.

Ultrasound-Activated Nanoparticles in Immune Cells Trigger Targeted Inflammatory Response

Boston College scientists demonstrated that barium titanate piezoelectric nanoparticles internalized by macrophages can be remotely activated with ultrasound, prompting M1‑type inflammatory polarization. By tuning ultrasound intensity they avoided cytotoxicity, while higher power levels selectively killed nanoparticle‑laden cells, hinting at a...

STAT+: Secretive Project Prometheus Takes VC Bob Nelsen Beyond Just Health Care

Venture capitalist Bob Nelsen is spearheading Project Prometheus, an AI‑driven venture that fuses artificial intelligence with physics. The startup is co‑led by Amazon founder Jeff Bezos and former Foresite Capital AI chief Vik Bajaj, with renowned scientist Rick Klausner on board. While...

Manufacturers Benefit as Pharma Customers Invest Back in US

Recent tariff and trade policy shifts that unsettled pharmaceutical firms in 2025 are now creating upside for U.S. manufacturers. Pharma companies are redirecting capital toward domestic production, spurring demand for contract manufacturing and equipment. This investment wave is expected to...

Future Outlook: SARS and COVID-19 Explained

The article offers a forward‑looking comparison of SARS and COVID‑19, detailing their virological differences, transmission dynamics, and the evolution of public‑health responses. It highlights how early containment strategies for SARS informed later COVID‑19 policies, while also exposing gaps in surveillance...

JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales

Sanofi’s CEO Paul Hudson said the firm will acquire Dynavax for $2.2 billion, targeting its adult hepatitis B vaccine Heplisav‑B, as vaccine sentiment wanes under U.S. political rhetoric. Legacy vaccine sales fell 8 % in Q3 2025, prompting a long‑term focus on adult‑focused products...

CRISPR–Cas3 Genome-Editing System Holds Therapeutic Potential

Researchers at the University of Tokyo demonstrated that the CRISPR‑Cas3 system can permanently suppress transthyretin (TTR) production in a mouse model of hereditary amyloidosis. Using lipid‑nanoparticle delivery, they achieved roughly 48% editing of hepatic TTR alleles and an 80% reduction...

Thoughts on Aging as Damage versus Aging as a Program of Altered Gene Expression

The article contrasts two dominant aging paradigms—damage accumulation and programmed gene‑expression—and highlights a growing synthesis of the two. It explains that a damage view drives research toward repair mechanisms, while a program view pushes gene‑expression and metabolic re‑engineering. Recent discoveries,...

Dycem, a contamination‑control specialist, celebrates 60 years since its 1966 founding, tracing roots to a high‑friction polymer discovered in 1960. The company grew from niche non‑slip products to global cleanroom solutions, now present in more than 50 countries and 30,000...

Nonlinear X-Ray Four-Photon Interaction Unveiled

Researchers have reported the first experimental observation of a nonlinear X‑ray four‑photon interaction, a phenomenon previously confined to theoretical models. The breakthrough was achieved using ultra‑intense pulses from a free‑electron laser, enabling simultaneous absorption of four X‑ray photons in a...

Jazz Sells Priority Review Voucher for $200M, Scoring Highest Price in a Decade

Jazz Pharmaceuticals announced the sale of a priority review voucher to an undisclosed buyer for $200 million, marking the highest price paid for such a voucher in a decade. The voucher, originally granted for developing a treatment for a neglected disease,...

Health Tech Funding Rounds Get Bigger when Andreessen Horowitz and General Catalyst Join

Rock Health’s latest report shows a handful of venture firms dominate health‑tech financing. When Andreessen Horowitz and General Catalyst join a round, the deal size expands dramatically, with average rounds climbing from roughly $30 million to $50 million. Together these two firms...

Program Harnesses the Power of Mentorship for Patient Organization Leaders

The Milken Institute’s FasterCures LeadersLink program, launched in 2020, provides mentorship, peer learning, and capstone projects for emerging leaders of patient advocacy organizations that fund or conduct biomedical research. The cohort‑based model connects mentees with seasoned executives, fostering strategic reflection...

A CRISPR Fingerprint of Pathogenic C. Auris Fungi for Precision Diagnostics

Researchers at Harvard’s Wyss Institute have unveiled dSHERLOCK, a digital CRISPR‑based diagnostic that can detect and quantify Candida auris from swab samples in under 40 minutes while simultaneously identifying antifungal resistance mutations. The platform merges SHERLOCK’s single‑nucleotide precision with single‑molecule...

Natural Fiber Welding Receives Investment From Provest Equity Partners and CTW Venture Partners

Natural Fiber Welding, a Peoria‑based developer of plant‑derived performance materials, secured a strategic investment from Provest Equity Partners and CTW Venture Partners. The undisclosed capital infusion coincides with Suhas Uppalapati joining the board as Chairman. The company will deploy the...

JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes

Gilead’s new HIV therapy Yeztugo is gaining rapid market traction, achieving 85% payer coverage six months after its June 2025 approval and hitting the $150 million revenue target for the year. CEO Daniel O’Day highlighted voluntary licensing of the drug’s active ingredient,...

2026 Outlook: ‘Slow-Moving Catastrophe’ at FDA

The FDA is entering a ‘slow‑moving catastrophe’ as staffing cuts, politicization, and the erosion of scientific expertise undermine its regulatory capacity. Senior leadership turnover and a hiring freeze have reduced review staff by roughly 15 percent, while political pressure accelerates...

Framework to Optimize Mammalian Cell Culture Media Blending

Researchers from Osaka University and Shimadzu introduced a mathematically precise workflow for chemically defined media (CDM) blending in mammalian cell culture. The three‑step process combines experimental design, cell culture testing, and regression modeling, using PCA to eliminate multicollinearity and D‑optimal...

Drugs From the Deep

Marine organisms have yielded over 40,000 natural compounds, with 13 now FDA‑approved for cancers, viral infections and chronic pain. The primary obstacle to expanding this "blue pharmaceutical" pipeline is supply, as many bioactive molecules occur in minute quantities that are...

Biologics Manufacturers Urged to Develop QC Plans Early

At an upcoming conference, French biotech consultancy INITS will urge biologics manufacturers to establish a chemistry, manufacturing and controls (CMC) management strategy for reference materials early in development. Regulators increasingly demand deep characterization of reference material, especially by Phase III, and...

Regulatory Support Helping Biopharma to Embrace Platform Technologies

Biopharma firms are increasingly adopting platform technologies—standardized manufacturing bases that can be customized with disease‑specific modules—to accelerate product development and cut costs. Experts cite the lipid nanoparticle system used for mRNA vaccines as a prime example, where swapping the mRNA...

Pharmacovigilance Awareness Among Saudi Healthcare Students

A recent cross‑sectional study surveyed 500 Saudi pharmacy and medical students to gauge their understanding of pharmacovigilance (PV). Only 35% demonstrated sufficient knowledge of adverse drug reaction (ADR) reporting, revealing significant curriculum gaps. The researchers recommend integrating mandatory PV modules...

Intermittent Hypobaric Pressure Fights Aging and Osteoporosis

A recent preclinical study demonstrates that intermittent hypobaric pressure (IHP) exposure can mitigate age‑related bone loss and reverse cellular aging markers. Mice subjected to 2‑hour hypobaric cycles three times a week showed a 12% increase in bone mineral density and...

ImmunityBio's Anktiva Lung Cancer Data; Glaukos' Glaucoma Implant Sales Disappoint

ImmunityBio announced that its lymphocyte‑stimulating agent Anktiva, combined with checkpoint inhibitors, restored immune cells and produced objective responses in a non‑small‑cell lung cancer (NSCLC) study. The data suggest the combination could enhance the efficacy of existing immunotherapies. Meanwhile, Glaukos reported...

First-Time Use of AI for Genetic Circuit Design Demonstrated in a Human Cell Line

Rice University researchers unveiled CLASSIC, a high‑throughput platform that couples long‑ and short‑read sequencing to generate millions of genetic‑circuit designs in human cells. By pairing this massive library with machine‑learning models, the team demonstrated the first AI‑driven design of functional...

Thermo Fisher to Lay Off 421 Workers as It Winds Down Lab Product Site in North Carolina

Thermo Fisher Scientific announced it will phase out operations at its laboratory products facility in Asheville, North Carolina, laying off 421 workers. The shutdown is slated to be completed by the end of 2026, ending the site’s production of consumables...

Hydrogel Cilia Set New Standard in Microrobotics

Scientists at the Max Planck Institute, HKUST and Koç University have created 18 µm hydrogel cilia that beat at 5‑40 Hz when driven by a 1.5 V electric field. Using two‑photon polymerization, they printed arrays of hundreds of these microactuators on a flexible substrate...

The AbbVie Strategy, a Company at an Inflection Point

AbbVie’s historic reliance on Humira has been upended by a 54.5% U.S. revenue drop as biosimilars entered in 2023, prompting a strategic pivot toward its next‑generation immunology drugs Skyrizi and Rinvoq. The company projects combined revenue of over $31 billion from...

FDA Seeks Changes to GLP-1, Flu Shot Labels

The FDA has asked manufacturers of GLP‑1 weight‑loss drugs, including Wegovy, Saxenda and Zepbound, to drop the suicide‑ideation warning after a comprehensive safety review found no elevated risk. The agency’s meta‑analysis of 91 trials involving more than 100,000 participants confirmed...

AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Product Launches

At the J.P. Morgan Healthcare Conference, AstraZeneca reaffirmed its ambition to generate $80 billion in revenue by 2030, a target now seen as attainable. The company highlighted three near‑term product launches—baxdrostat for hypertension, camizestrant for breast cancer, and gefurulimab for myasthenia...

Super-Resolution Ultrasound Reveals Brain Issues in Parkinson’s

A new super‑resolution ultrasound technique can visualize microvascular abnormalities in the brains of Parkinson's patients with unprecedented clarity. In a study of 120 early‑stage participants, the method identified vascular biomarkers up to five years before clinical symptoms appeared. The non‑invasive...